Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Maccura Biotechnology Co. Ltd. operates in the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions. These actions are both located within 1 distinct art unit. Prosecution is handled by 2 distinct examiners. CYNTHIA B WILDER is the busiest examiner, with 1 pending action.
The presence of the 2 distinct examiners within the 1 distinct art unit for the 2 pending actions shows that while the technology is concentrated, the personnel reviewing it are diverse. For a Biotechnology & Pharmaceuticals portfolio, this specific art unit serves as the primary hub for current prosecution activity.
Having the distinct examiners for the actions ensures that the company's filings are being reviewed by different people, even though they fall under the same technical classification. This distribution may provide the company with different perspectives on how its Biotechnology & Pharmaceuticals innovations are viewed within the art unit. Practitioners should be aware that the pending actions are being handled independently by the examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILDER, CYNTHIA B | 1 | 70.8% | +27.0% |
| BERTAGNA, ANGELA MARIE | 1 | 44.7% | +46.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18027971 | MULTIPLEX NUCLEIC ACID DETECTION METHOD, COMPOSITION AND KIT | BERTAGNA, ANGELA MARIE | 21d |
| 18724405 | PRIMER PROBE FOR DETECTION, PRIMER PROBE SET, AND APPLICATION THEREOF | WILDER, CYNTHIA B | — |
| Art Unit | Apps |
|---|---|
| 1681 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724405 | PRIMER PROBE FOR DETECTION, PRIMER PROBE SET, AND APPLICATION THEREOF | WILDER, CYNTHIA B | 1681 | §112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18027971 | MULTIPLEX NUCLEIC ACID DETECTION METHOD, COMPOSITION AND KIT | BERTAGNA, ANGELA MARIE | 1681 | §112 | Final Rejection | 21d | Pending | Mar 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMaccura Biotechnology Co. Ltd. has 2 pending office actions as of October 2026, spread across 1 art units and 2 examiners.
Cynthia B Wilder has the most, with 1 of Maccura Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
